Abstract Library

#2874 Role of FOXM1 in Aggressive Pancreatic / Pulmonary Neuroendocrine Carcinomas and Anti-Tumor Effect of the FOXM1 Inhibitor Thiostrepton

Introduction: DNA-targeting agents are the main treatment of aggressive pulmonary and pancreatic neuroendocrine carcinomas (NEC). FOXM1 is a transcription factor controlling cell proliferation and DNA repair pathways, playing therefore an important role in tumor progression and chemoresistance.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: De Rycke O, Raffenne J, Lacombe C, Hentic O, Gounant V,

Keywords: neuroendocrine carcinoma, FOXM1, DNA repair, anti-tumor drug,

#2279 Expression of FOXM1 in G3 Neuroendocrine Tumors (NET G3) and G3 Neuroendocrine Carcinomas (NEC G3) of the Pancreas and the Intestine

Introduction: G3 gastroenteropancreatic neuroendocrine tumors (G3 NET) and carcinomas (G3 NEC) differ considerably concerning their biological behavior and patients outcome. Whereas the WHO2017 classification for pancreatic NETs proposes a distinction of both groups using the Ki-67 proliferation marker (Klöppel et al. Reviews and Reports 2017), a useful marker for the subclassification of G3 intestinal NETs have not been recommended until now.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Briest F

Authors: Briest F, Konukiewitz B, Anlauf M, Klöppel G, Grabowski P,

Keywords: gastroenteropancreatic neuroendocrine tumors, GEP-NET, NET G3, NEC G3, Tumor marker, FOXM1, Ki-67, differentiation,

#1810 FOXM1 Is Strongly Associated with Cell Proliferation and Is Not Influenced by Metabolic Syndrome in GEP-NETS

Introduction: Gastro-entero-pancreatic neuroendocrine tumors(GEP-NETs) and metabolic syndrome(MS) are both increasing exponentially. MS has been associated with several non NET cancers.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Pereira R

Authors: Pereira R, Pereira S, Morais T, Costa M, Sampaio P,

Keywords: GEP-NETs, metabolic syndrome, FOXM1, IGF1R, IL-6, Ki67 ,

#1003 Signalling Pathways in Bronchial Neuroendocrine Tumor Disease and Its Translation to Innovative Targets: The New Kid on the Block

Introduction: Bronchial neuroendocrine neoplasias comprise a wide spectrum of well-differentiated tumors (typical/atypical carcinoids) to undifferentiated carcinomas such as small (SCLC) and large cell (LC) neuroendocrine carcinomas with a fatal prognosis. Therapeutic options are unsatisfactory.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Lewens F

Authors: Lewens F, Freitag H, Briest F, Heilmann M, Schneider C,

Keywords: bronchial, NETs, PI3K, FoxM1, survivin, cell lines, SCLC,

#1001 Forkheadbox Proteins as Novel Drug Targets in Gastroenteropancreatic Neuroendocrine Tumor Disease: Inhibition of FoxM1 Exerts Antiproliferative Effects in GEP-NEN Cell Lines

Introduction: Forkheadbox proteins (Fox proteins) are transcriptions factors. They are highly conserved key players in a large number of cellular processes. Fox proteins have been described as acting as both tumor suppressors and oncogenes. Most notably, they operate in the context of the majority of cancer-related pathways. Information about the fuunction of these proteins in gastroenteropancreatic neuroendocrine neoplasias is scant.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Briest F

Authors: Briest F, Freitag H, Lewens F, Kaemmerer D, Hörsch D,

Keywords: Forkheadbox proteins, signalling network, immunohistochemistry, siRNA, microarray technique,